Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Gastrointestinal inflammation? 441 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 441 reports of Gastrointestinal inflammation have been filed in association with INFLIXIMAB (Renflexis). This represents 0.3% of all adverse event reports for INFLIXIMAB.

441
Reports of Gastrointestinal inflammation with INFLIXIMAB
0.3%
of all INFLIXIMAB reports
2
Deaths
160
Hospitalizations

How Dangerous Is Gastrointestinal inflammation From INFLIXIMAB?

Of the 441 reports, 2 (0.5%) resulted in death, 160 (36.3%) required hospitalization, and 3 (0.7%) were considered life-threatening.

Is Gastrointestinal inflammation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 441 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Gastrointestinal inflammation?

ADALIMUMAB (2,170) VEDOLIZUMAB (530) METHOTREXATE (218) RISANKIZUMAB-RZAA (157) USTEKINUMAB (141) PREDNISONE (121) CAPECITABINE (94) INFLIXIMAB-DYYB (92) HUMIRA (91) RITUXIMAB (90)

Which INFLIXIMAB Alternatives Have Lower Gastrointestinal inflammation Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Gastrointestinal inflammation Reports All Drugs Causing Gastrointestinal inflammation INFLIXIMAB Demographics